Melanotan-II

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 597493

CAS#: 121062-08-6 (free base)

Description: Melanotan-II is a synthetic cyclic heptapeptide, an analog of alpha-melanotropin (4,10); capable of stimulating melanin synthesis & promoting rapid tanning of skin; currently in trials for use in the prevention of sunlight-induced skin cancer.

Chemical Structure

img
Melanotan-II
CAS# 121062-08-6 (free base)
Instruction

Theoretical Analysis

MedKoo Cat#: 597493
Name: Melanotan-II
CAS#: 121062-08-6 (free base)
Chemical Formula: C50H69N15O9
Exact Mass: 1,023.54
Molecular Weight: 1,024.190
Elemental Analysis: C, 58.64; H, 6.79; N, 20.51; O, 14.06

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Related CAS #: Melanotan II acetate   121062-08-6 (free base)    

Synonym: Melanotan-II; Melanotan II; MelanotanII;

IUPAC/Chemical Name: (3S,6S,9R,12S,15S,23S)-12-((1H-imidazol-5-yl)methyl)-3-((1H-indol-3-yl)methyl)-15-((S)-2-acetamidohexanamido)-9-benzyl-6-(3-guanidinopropyl)-2,5,8,11,14,17-hexaoxo-1,4,7,10,13,18-hexaazacyclotricosane-23-carboxamide

InChi Key: JDKLPDJLXHXHNV-MFVUMRCOSA-N

InChi Code: 1S/C50H69N15O9/c1-3-4-16-36(59-29(2)66)44(69)65-41-25-42(67)55-20-11-10-18-35(43(51)68)60-47(72)39(23-31-26-57-34-17-9-8-15-33(31)34)63-45(70)37(19-12-21-56-50(52)53)61-46(71)38(22-30-13-6-5-7-14-30)62-48(73)40(64-49(41)74)24-32-27-54-28-58-32/h5-9,13-15,17,26-28,35-41,57H,3-4,10-12,16,18-25H2,1-2H3,(H2,51,68)(H,54,58)(H,55,67)(H,59,66)(H,60,72)(H,61,71)(H,62,73)(H,63,70)(H,64,74)(H,65,69)(H4,52,53,56)/t35-,36-,37-,38+,39-,40-,41-/m0/s1

SMILES Code: O=C(N[C@H](Cc1ccccc1)C(N[C@@H](CCCNC(N)=N)C(N[C@H](C(N[C@H](C(N)=O)CCCCNC(C[C@H](NC([C@@H](NC(C)=O)CCCC)=O)C(N2)=O)=O)=O)Cc(c[nH]3)c4c3cccc4)=O)=O)[C@@H]2Cc5[nH]cnc5

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.03.00

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 1,024.19 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Hjuler KF, Lorentzen HF. Melanoma associated with the use of melanotan-II. Dermatology. 2014;228(1):34-6. doi: 10.1159/000356389. Epub 2013 Dec 18. PubMed PMID: 24355990.

2: Breindahl T, Evans-Brown M, Hindersson P, McVeigh J, Bellis M, Stensballe A, Kimergård A. Identification and characterization by LC-UV-MS/MS of melanotan II skin-tanning products sold illegally on the Internet. Drug Test Anal. 2015 Feb;7(2):164-72. doi: 10.1002/dta.1655. Epub 2014 Apr 25. PubMed PMID: 24771717.

3: Monge-Roffarello B, Labbe SM, Lenglos C, Caron A, Lanfray D, Samson P, Richard D. The medial preoptic nucleus as a site of the thermogenic and metabolic actions of melanotan II in male rats. Am J Physiol Regul Integr Comp Physiol. 2014 Jul 15;307(2):R158-66. PubMed PMID: 24808495.

4: Olney JJ, Sprow GM, Navarro M, Thiele TE. The protective effects of the melanocortin receptor (MCR) agonist, melanotan-II (MTII), against binge-like ethanol drinking are facilitated by deletion of the MC3 receptor in mice. Neuropeptides. 2014 Feb;48(1):47-51. doi: 10.1016/j.npep.2013.11.001. Epub 2013 Nov 15. PubMed PMID: 24290566; PubMed Central PMCID: PMC3946855.

5: Navarro M, Carvajal F, Lerma-Cabrera JM, Cubero I, Picker MJ, Thiele TE. Evidence that Melanocortin Receptor Agonist Melanotan-II Synergistically Augments the Ability of Naltrexone to Blunt Binge-Like Ethanol Intake in Male C57BL/6J Mice. Alcohol Clin Exp Res. 2015 Aug;39(8):1425-33. doi: 10.1111/acer.12774. Epub 2015 Jun 24. PubMed PMID: 26108334; PubMed Central PMCID: PMC4515169.

6: Nelson ME, Bryant SM, Aks SE. Melanotan II injection resulting in systemic toxicity and rhabdomyolysis. Clin Toxicol (Phila). 2012 Dec;50(10):1169-73. doi: 10.3109/15563650.2012.740637. Epub 2012 Nov 5. PubMed PMID: 23121206.

7: Burian E, Burian E. [Eruptive nevi after injection of drugs marketed as melanotan II. The first two Swedish cases described]. Lakartidningen. 2013 Jan 30-Feb 5;110(5):208-10. Swedish. PubMed PMID: 23451671.

8: van den Heuvel JK, Eggels L, van Rozen AJ, Fliers E, Kalsbeek A, Adan RA, la Fleur SE. Inhibitory Effect of the Melanocortin Receptor Agonist Melanotan-II (MTII) on Feeding Depends on Dietary Fat Content and not Obesity in Rats on Free-Choice Diets. Front Behav Neurosci. 2015 Dec 24;9:358. doi: 10.3389/fnbeh.2015.00358. eCollection 2015. PubMed PMID: 26733840; PubMed Central PMCID: PMC4689860.

9: Mahiques-Santos L. [Melanotan]. Actas Dermosifiliogr. 2012 May;103(4):257-9. doi: 10.1016/j.ad.2011.08.002. Epub 2011 Nov 1. Spanish. PubMed PMID: 22051769.

10: Dorr RT, Lines R, Levine N, Brooks C, Xiang L, Hruby VJ, Hadley ME. Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. Life Sci. 1996;58(20):1777-84. PubMed PMID: 8637402.

11: Ter Laak MP, Brakkee JH, Adan RA, Hamers FP, Gispen WH. The potent melanocortin receptor agonist melanotan-II promotes peripheral nerve regeneration and has neuroprotective properties in the rat. Eur J Pharmacol. 2003 Feb 21;462(1-3):179-83. PubMed PMID: 12591111.

12: Ong S, Bowling J. Melanotan-associated melanoma in situ. Australas J Dermatol. 2012 Nov;53(4):301-2. doi: 10.1111/j.1440-0960.2012.00915.x. Epub 2012 Jun 22. PubMed PMID: 22724573.

13: De Jonghe BC, Hayes MR, Zimmer DJ, Kanoski SE, Grill HJ, Bence KK. Food intake reductions and increases in energetic responses by hindbrain leptin and melanotan II are enhanced in mice with POMC-specific PTP1B deficiency. Am J Physiol Endocrinol Metab. 2012 Sep 1;303(5):E644-51. doi: 10.1152/ajpendo.00009.2012. Epub 2012 Jul 3. PubMed PMID: 22761160; PubMed Central PMCID: PMC3468506.

14: Wolters FL, de Vocht TF, Klis SF, Hamers FP, Smoorenburg GF. Co-treatment with melanotan-II, a potent melanocortin, does not protect against cisplatin ototoxicity. Hear Res. 2002 Oct;172(1-2):110-7. PubMed PMID: 12361873.

15: Giuliano F, Clément P, Droupy S, Alexandre L, Bernabé J. Melanotan-II: Investigation of the inducer and facilitator effects on penile erection in anaesthetized rat. Neuroscience. 2006;138(1):293-301. Epub 2005 Dec 19. PubMed PMID: 16360286.

16: Rössler AS, Pfaus JG, Kia HK, Bernabé J, Alexandre L, Giuliano F. The melanocortin agonist, melanotan II, enhances proceptive sexual behaviors in the female rat. Pharmacol Biochem Behav. 2006 Nov;85(3):514-21. Epub 2006 Nov 20. PubMed PMID: 17113634.

17: Wang J, Ling S, Usami T, Murata T, Narita K, Higuchi T. Effects of ghrelin, corticotrophin-releasing hormone, and melanotan-II on food intake in rats with paraventricular nucleus lesions. Exp Clin Endocrinol Diabetes. 2007 Nov;115(10):669-73. PubMed PMID: 18058602.

18: Giuliano F, Rössler AS, Clément P, Droupy S, Alexandre L, Bernabé J. The use of telemetry technology to test the proerectile effect of melanotan-II (MT-II) in conscious rats. Eur Urol. 2005 Jul;48(1):145-51; discussion 151-2. Epub 2005 Mar 20. PubMed PMID: 15967265.

19: Kilpeläinen M, Mönkäre J, Vlasova MA, Riikonen J, Lehto VP, Salonen J, Järvinen K, Herzig KH. Nanostructured porous silicon microparticles enable sustained peptide (Melanotan II) delivery. Eur J Pharm Biopharm. 2011 Jan;77(1):20-5. doi: 10.1016/j.ejpb.2010.10.004. Epub 2010 Oct 20. PubMed PMID: 20965250.

20: Lan EL, Ugwu SO, Blanchard J, Fang X, Hruby VJ, Sharma S. Preformulation studies with melanotan-II: a potential skin cancer chemopreventive peptide. J Pharm Sci. 1994 Aug;83(8):1081-4. PubMed PMID: 7983590.